search
Back to results

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
tiotropium-bromide
tiotropium-bromide
placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

1 Year - 5 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. All patients' parents (or legal guardians) must sign and date an informed consent consistent with ICH-GCP guidelines and local legislation prior to participation in the trial. Where appropriate, participants should assent to enroll in the study.
  2. Male or female patients between 1 and 5 years of age.
  3. By a physician documented (at least 6 month) history of persistent asthma symptoms, including (but not limited to) wheezing, cough, and/or shortness of breath. (persistent = need for inhalation corticosteroid maintenance therapy to control asthma symptoms)
  4. For patients aged 5 years and capable of performing technically acceptable Pulmonary Function tests (PFTs): documented impaired lung function (i.e. pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is smaller or equal to 90% of predicted normal).
  5. All patients must have been on maintenance treatment with an inhaled corticosteroid at stable dose, either as mono treatment or in combination with another controller medication, for at least 4 weeks before Visit 1.
  6. All patients must be symptomatic (partly controlled) as defined by the Global Initiative for Asthma (GINA) guideline for children aged 5 years and younger in the week prior to Visit 1 (screening) and in the week prior to randomisation (Visit 2).

Further inclusion criteria apply.

Exclusion criteria:

  1. Patients with a significant disease other than asthma.
  2. Patients with clinically relevant abnormal screening haematology or blood chemistry will be excluded if the abnormality defines a significant disease as defined in exclusion criterion 1.
  3. Patients with a history of congenital or acquired heart disease, or patients who have been hospitalised for cardiac syncope or failure during the past year.
  4. Patients with any unstable or life-threatening cardiac arrhythmia, including cardiac arrhythmia requiring intervention (e.g. pacemaker implantation) or a change in drug therapy within the past year.
  5. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy.
  6. Patients with clinically significant lung diseases other than asthma.
  7. Alternative causes (other causes than asthma) that can lead to respiratory symptoms of wheeze, cough and shortness of breath.
  8. Patients with known active tuberculosis.
  9. Patients who have undergone thoracotomy with pulmonary resection.
  10. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit 1).

Further exclusion criteria apply.

Sites / Locations

  • 205.443.12003 Boehringer Ingelheim Investigational Site
  • 205.443.12005 Boehringer Ingelheim Investigational Site
  • 205.443.12006 Boehringer Ingelheim Investigational Site
  • 205.443.12004 Boehringer Ingelheim Investigational Site
  • 205.443.01004 Boehringer Ingelheim Investigational Site
  • 205.443.01002 Boehringer Ingelheim Investigational Site
  • 205.443.01001 Boehringer Ingelheim Investigational Site
  • 205.443.02002 Boehringer Ingelheim Investigational Site
  • 205.443.02003 Boehringer Ingelheim Investigational Site
  • 205.443.03003 Boehringer Ingelheim Investigational Site
  • 205.443.03001 Boehringer Ingelheim Investigational Site
  • 205.443.03002 Boehringer Ingelheim Investigational Site
  • 205.443.03010 Boehringer Ingelheim Investigational Site
  • 205.443.82003 Boehringer Ingelheim Investigational Site
  • 205.443.82002 Boehringer Ingelheim Investigational Site
  • 205.443.82001 Boehringer Ingelheim Investigational Site
  • 205.443.05001 Boehringer Ingelheim Investigational Site
  • 205.443.05003 Boehringer Ingelheim Investigational Site
  • 205.443.05002 Boehringer Ingelheim Investigational Site
  • 205.443.06002 Boehringer Ingelheim Investigational Site
  • 205.443.06003 Boehringer Ingelheim Investigational Site
  • 205.443.10002 Boehringer Ingelheim Investigational Site
  • 205.443.10001 Boehringer Ingelheim Investigational Site
  • 205.443.10003 Boehringer Ingelheim Investigational Site
  • 205.443.04003 Boehringer Ingelheim Investigational Site
  • 205.443.04001 Boehringer Ingelheim Investigational Site
  • 205.443.09001 Boehringer Ingelheim Investigational Site
  • 205.443.09002 Boehringer Ingelheim Investigational Site
  • 205.443.07003 Boehringer Ingelheim Investigational Site
  • 205.443.07002 Boehringer Ingelheim Investigational Site
  • 205.443.07005 Boehringer Ingelheim Investigational Site
  • 205.443.07004 Boehringer Ingelheim Investigational Site
  • 205.443.07001 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

tiotropium low dose

tiotropium high dose

placebo

Arm Description

Once daily, delivered with Respimat® inhaler

Once daily, delivered with Respimat® inhaler

Once daily, delivered with Respimat® inhaler

Outcomes

Primary Outcome Measures

Weekly Mean Combined Daytime Asthma Symptom Score
Change from baseline in the weekly mean combined daytime asthma symptom score as assessed by the Paediatric Asthma Caregivers Diary (PACD) in the last week of the 12 week treatment period. The PACD is a diary designed to evaluate daily asthma symptoms in children aged 2-5 years. The diary consists of three questions to be answered each morning, when the child wakes up, and seven questions to be answered each evening, right after the child goes to bed for the night. A week was defined as 7 days. The combined daytime score is the average of scores from questions 4 - 7 in the diary which are questions regarding severity of cough, wheezing, trouble breathing and interference with activities, scores for each question range from 0 (best) to 5 (worst). The week 12 weekly mean is the mean of the responses for each day averaged over the 7 days in week 12, so combined daytime asthma symptom scores also range from 0 (best) to 5 (worst). The measured values presented are adjusted means.
FEV1 Peak (0-3h) Change From Baseline
Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak (0-3h)) measured at week 12

Secondary Outcome Measures

Weekly Mean Overnight Asthma Symptom Score Response
Change from baseline in the weekly mean overnight asthma symptom score response as assessed by the PACD in the last week of the 12 week treatment period. The overnight score is the score from the following question in the PACD, "How much did your child cough last night after your child was put to bed for the night until he/she awoke this morning?". This endpoint was determined only for patients with 2 or more nights with symptoms per week during the baseline period. In this case, the baseline period is the 7 days used to derive the baseline value. A patient has a night with symptoms if the question was answered with scores 1, 2, 3, 4 or 5 or the patient received β-Agonist at least one time since he/she went to bed. A week was defined as 7 days. Scores range from 0 (best) to 4 (worst), a value of 5 indicates severity of symptoms is unknown. The measured values presented are adjusted means
Weekly Percentage of Days Without Asthma Symptoms
Weekly Percentage of days without asthma symptoms at week 12. A day without asthma symptoms was defined as a day during which the patient experienced no asthma symptoms, did not use rescue medication (salbutamol/albuterol) and had no asthma exacerbation/worsening requiring systemic corticosteroids, or unscheduled visits to a doctor's office, emergency department, or hospital. A week was defined as 7 days. The measured values presented are adjusted means
Weekly Percentage of Days With Use of Salbutamol (Albuterol) Rescue Medication
Weekly percentage of days with use of salbutamol (albuterol) rescue medication at week 12. A week was defined as 7 days.
Weekly Mean Nighttime Awakenings Due to Asthma Symptoms
Change from baseline in the weekly mean nighttime awakenings due to asthma symptoms as assessed by the PACD, in the last week of the 12 week treatment period. The weekly mean was calculated as the average of the weekly scores for the question "Did your child wake up during the night due to his/her asthma?" The question was answered on a 5-point verbal rating scale, with scores ranging from 1 (did not wake up) to 5 (was awake all night). A week was defined as 7 days. The measured values presented are adjusted means
Trough FEV1 Change From Baseline
Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.
FEV1 AUC (0-3h) Change From Baseline
Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
FVC Peak (0-3h) Change From Baseline
Change from baseline in maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak (0-3h)) after 12 weeks of treatment.
Trough FVC Change From Baseline
Change from baseline of trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 12 weeks of treatment.
FVC AUC (0-3h) Change From Baseline
Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Individual FEV1 Measurements
Change from baseline in individual FEV1 measurements at each timepoint after 12 weeks
Individual FVC Measurements
Change from baseline in individual FVC measurements at each timepoint after 12 weeks

Full Information

First Posted
April 16, 2012
Last Updated
June 3, 2015
Sponsor
Boehringer Ingelheim
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT01634113
Brief Title
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
Official Title
A Phase II/III, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution (2.5 µg and 5 µg) Administered Once Daily in the Afternoon Via Respimat® Inhaler for 12 Weeks in Patients 1 to 5 Years Old With Persistent Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Pfizer

4. Oversight

5. Study Description

Brief Summary
The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the afternoon in patients (1 to 5 years old) with persistent asthma on top of inhaled corticosteroid (ICS) treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
102 (Actual)

8. Arms, Groups, and Interventions

Arm Title
tiotropium low dose
Arm Type
Experimental
Arm Description
Once daily, delivered with Respimat® inhaler
Arm Title
tiotropium high dose
Arm Type
Experimental
Arm Description
Once daily, delivered with Respimat® inhaler
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Once daily, delivered with Respimat® inhaler
Intervention Type
Drug
Intervention Name(s)
tiotropium-bromide
Intervention Description
IMP
Intervention Type
Drug
Intervention Name(s)
tiotropium-bromide
Intervention Description
IMP
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo matching tiotropium
Primary Outcome Measure Information:
Title
Weekly Mean Combined Daytime Asthma Symptom Score
Description
Change from baseline in the weekly mean combined daytime asthma symptom score as assessed by the Paediatric Asthma Caregivers Diary (PACD) in the last week of the 12 week treatment period. The PACD is a diary designed to evaluate daily asthma symptoms in children aged 2-5 years. The diary consists of three questions to be answered each morning, when the child wakes up, and seven questions to be answered each evening, right after the child goes to bed for the night. A week was defined as 7 days. The combined daytime score is the average of scores from questions 4 - 7 in the diary which are questions regarding severity of cough, wheezing, trouble breathing and interference with activities, scores for each question range from 0 (best) to 5 (worst). The week 12 weekly mean is the mean of the responses for each day averaged over the 7 days in week 12, so combined daytime asthma symptom scores also range from 0 (best) to 5 (worst). The measured values presented are adjusted means.
Time Frame
Baseline and 12 weeks
Title
FEV1 Peak (0-3h) Change From Baseline
Description
Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak (0-3h)) measured at week 12
Time Frame
10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12
Secondary Outcome Measure Information:
Title
Weekly Mean Overnight Asthma Symptom Score Response
Description
Change from baseline in the weekly mean overnight asthma symptom score response as assessed by the PACD in the last week of the 12 week treatment period. The overnight score is the score from the following question in the PACD, "How much did your child cough last night after your child was put to bed for the night until he/she awoke this morning?". This endpoint was determined only for patients with 2 or more nights with symptoms per week during the baseline period. In this case, the baseline period is the 7 days used to derive the baseline value. A patient has a night with symptoms if the question was answered with scores 1, 2, 3, 4 or 5 or the patient received β-Agonist at least one time since he/she went to bed. A week was defined as 7 days. Scores range from 0 (best) to 4 (worst), a value of 5 indicates severity of symptoms is unknown. The measured values presented are adjusted means
Time Frame
Baseline and 12 weeks
Title
Weekly Percentage of Days Without Asthma Symptoms
Description
Weekly Percentage of days without asthma symptoms at week 12. A day without asthma symptoms was defined as a day during which the patient experienced no asthma symptoms, did not use rescue medication (salbutamol/albuterol) and had no asthma exacerbation/worsening requiring systemic corticosteroids, or unscheduled visits to a doctor's office, emergency department, or hospital. A week was defined as 7 days. The measured values presented are adjusted means
Time Frame
12 weeks
Title
Weekly Percentage of Days With Use of Salbutamol (Albuterol) Rescue Medication
Description
Weekly percentage of days with use of salbutamol (albuterol) rescue medication at week 12. A week was defined as 7 days.
Time Frame
12 weeks
Title
Weekly Mean Nighttime Awakenings Due to Asthma Symptoms
Description
Change from baseline in the weekly mean nighttime awakenings due to asthma symptoms as assessed by the PACD, in the last week of the 12 week treatment period. The weekly mean was calculated as the average of the weekly scores for the question "Did your child wake up during the night due to his/her asthma?" The question was answered on a 5-point verbal rating scale, with scores ranging from 1 (did not wake up) to 5 (was awake all night). A week was defined as 7 days. The measured values presented are adjusted means
Time Frame
Baseline and 12 weeks
Title
Trough FEV1 Change From Baseline
Description
Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.
Time Frame
Baseline and 12 weeks
Title
FEV1 AUC (0-3h) Change From Baseline
Description
Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Time Frame
10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12
Title
FVC Peak (0-3h) Change From Baseline
Description
Change from baseline in maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak (0-3h)) after 12 weeks of treatment.
Time Frame
10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12
Title
Trough FVC Change From Baseline
Description
Change from baseline of trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 12 weeks of treatment.
Time Frame
Baseline and 12 weeks
Title
FVC AUC (0-3h) Change From Baseline
Description
Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Time Frame
10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12
Title
Individual FEV1 Measurements
Description
Change from baseline in individual FEV1 measurements at each timepoint after 12 weeks
Time Frame
Baseline and 12 weeks
Title
Individual FVC Measurements
Description
Change from baseline in individual FVC measurements at each timepoint after 12 weeks
Time Frame
Baseline and 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: All patients' parents (or legal guardians) must sign and date an informed consent consistent with ICH-GCP guidelines and local legislation prior to participation in the trial. Where appropriate, participants should assent to enroll in the study. Male or female patients between 1 and 5 years of age. By a physician documented (at least 6 month) history of persistent asthma symptoms, including (but not limited to) wheezing, cough, and/or shortness of breath. (persistent = need for inhalation corticosteroid maintenance therapy to control asthma symptoms) For patients aged 5 years and capable of performing technically acceptable Pulmonary Function tests (PFTs): documented impaired lung function (i.e. pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is smaller or equal to 90% of predicted normal). All patients must have been on maintenance treatment with an inhaled corticosteroid at stable dose, either as mono treatment or in combination with another controller medication, for at least 4 weeks before Visit 1. All patients must be symptomatic (partly controlled) as defined by the Global Initiative for Asthma (GINA) guideline for children aged 5 years and younger in the week prior to Visit 1 (screening) and in the week prior to randomisation (Visit 2). Further inclusion criteria apply. Exclusion criteria: Patients with a significant disease other than asthma. Patients with clinically relevant abnormal screening haematology or blood chemistry will be excluded if the abnormality defines a significant disease as defined in exclusion criterion 1. Patients with a history of congenital or acquired heart disease, or patients who have been hospitalised for cardiac syncope or failure during the past year. Patients with any unstable or life-threatening cardiac arrhythmia, including cardiac arrhythmia requiring intervention (e.g. pacemaker implantation) or a change in drug therapy within the past year. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy. Patients with clinically significant lung diseases other than asthma. Alternative causes (other causes than asthma) that can lead to respiratory symptoms of wheeze, cough and shortness of breath. Patients with known active tuberculosis. Patients who have undergone thoracotomy with pulmonary resection. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit 1). Further exclusion criteria apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
205.443.12003 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
Missouri
Country
United States
Facility Name
205.443.12005 Boehringer Ingelheim Investigational Site
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
205.443.12006 Boehringer Ingelheim Investigational Site
City
Charleston
State/Province
South Carolina
Country
United States
Facility Name
205.443.12004 Boehringer Ingelheim Investigational Site
City
Summerville
State/Province
South Carolina
Country
United States
Facility Name
205.443.01004 Boehringer Ingelheim Investigational Site
City
Antwerpen
Country
Belgium
Facility Name
205.443.01002 Boehringer Ingelheim Investigational Site
City
Brussel
Country
Belgium
Facility Name
205.443.01001 Boehringer Ingelheim Investigational Site
City
Edegem
Country
Belgium
Facility Name
205.443.02002 Boehringer Ingelheim Investigational Site
City
Helsinki
Country
Finland
Facility Name
205.443.02003 Boehringer Ingelheim Investigational Site
City
Turku
Country
Finland
Facility Name
205.443.03003 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
205.443.03001 Boehringer Ingelheim Investigational Site
City
Bochum
Country
Germany
Facility Name
205.443.03002 Boehringer Ingelheim Investigational Site
City
Ettenheim
Country
Germany
Facility Name
205.443.03010 Boehringer Ingelheim Investigational Site
City
Frankfurt
Country
Germany
Facility Name
205.443.82003 Boehringer Ingelheim Investigational Site
City
Guri
Country
Korea, Republic of
Facility Name
205.443.82002 Boehringer Ingelheim Investigational Site
City
Incheon
Country
Korea, Republic of
Facility Name
205.443.82001 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
205.443.05001 Boehringer Ingelheim Investigational Site
City
Balvi
Country
Latvia
Facility Name
205.443.05003 Boehringer Ingelheim Investigational Site
City
Rezekne
Country
Latvia
Facility Name
205.443.05002 Boehringer Ingelheim Investigational Site
City
Riga
Country
Latvia
Facility Name
205.443.06002 Boehringer Ingelheim Investigational Site
City
Vilnius
Country
Lithuania
Facility Name
205.443.06003 Boehringer Ingelheim Investigational Site
City
Vilnius
Country
Lithuania
Facility Name
205.443.10002 Boehringer Ingelheim Investigational Site
City
Kelantan
Country
Malaysia
Facility Name
205.443.10001 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
205.443.10003 Boehringer Ingelheim Investigational Site
City
Pahang
Country
Malaysia
Facility Name
205.443.04003 Boehringer Ingelheim Investigational Site
City
Breda
Country
Netherlands
Facility Name
205.443.04001 Boehringer Ingelheim Investigational Site
City
Groningen
Country
Netherlands
Facility Name
205.443.09001 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
205.443.09002 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
205.443.07003 Boehringer Ingelheim Investigational Site
City
Dnipropetrovsk
Country
Ukraine
Facility Name
205.443.07002 Boehringer Ingelheim Investigational Site
City
Donetsk
Country
Ukraine
Facility Name
205.443.07005 Boehringer Ingelheim Investigational Site
City
Vinnytsya
Country
Ukraine
Facility Name
205.443.07004 Boehringer Ingelheim Investigational Site
City
Zaporizhya
Country
Ukraine
Facility Name
205.443.07001 Boehringer Ingelheim Investigational Site
City
Zaporizhzhya
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
29605203
Citation
Wachtel H, Nagel M, Engel M, El Azzi G, Sharma A, Suggett J. In vitro and clinical characterization of the valved holding chamber AeroChamber Plus(R) Flow-Vu(R) for administrating tiotropium Respimat(R) in 1-5-year-old children with persistent asthmatic symptoms. Respir Med. 2018 Apr;137:181-190. doi: 10.1016/j.rmed.2018.03.010. Epub 2018 Mar 7.
Results Reference
derived
PubMed Identifier
29361462
Citation
Vrijlandt EJLE, El Azzi G, Vandewalker M, Rupp N, Harper T, Graham L, Szefler SJ, Moroni-Zentgraf P, Sharma A, Vulcu SD, Sigmund R, Chawes B, Engel M, Bisgaard H. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018 Feb;6(2):127-137. doi: 10.1016/S2213-2600(18)30012-2. Epub 2018 Jan 18.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/
Description
Related Info

Learn more about this trial

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

We'll reach out to this number within 24 hrs